<DOC>
	<DOCNO>NCT01893866</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetic comparability 1x30 mg pegvisomant injection administer single 1 mL injection versus 2x15 mg/mL pegvisomant administer two separate 1 mL injection characterize pharmacokinetics new 30 mg strength .</brief_summary>
	<brief_title>A Relative Bioavailability Study To Evaluate Safety , Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . Evidence personally sign date informed consent document indicate subject ( legal representative ) inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Treatment investigational drug within 30 day 5 half life precede first dose study medication . 12 lead ECG demonstrate QTc &gt; 450 msec Screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Pregnant female ; breastfeed female ; male females childbearing potential unwilling unable use highly effective method nonhormonal contraception outline protocol duration study least 28 day last dose investigational product . Male subject unwilling use effective contraception ( eg , barrier abstinence ) study . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication . Herbal supplement hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesterone releasing IUDs , postcoital contraceptive method ) hormone replacement therapy must discontinue 28 day prior first dose study medication . Depo Provera must discontinue least 6 month prior first dose study medication . As exception , acetaminophen/paracetamol may use dos 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . History hypersensitivity pegvisomant component formulation , material vial , include latex . Subjects allergic latex exclude . Unwilling unable comply Lifestyle Guidelines describe protocol . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>